Confined or spread disease-Spread to regional lymph nodes Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread to regional lymph nodes Posts on Medivizor

Comparing the long-term effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Comparing the long-term effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Posted by on Jun 11, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of trastuzumab deruxtecan (TD; Enhertu) with trastuzumab emtansine (TE; Kadcyla) in patients with HER2-positive (HER2+) metastatic breast cancer (BC). The study found that TD was more effective and well-tolerated compared to TE in these patients. Some background HER2+ BC...

Read More

Evaluating the long-term effectiveness and safety of palbociclib plus fulvestrant treatment in patients with HR+/HER2- advanced BC.

Evaluating the long-term effectiveness and safety of palbociclib plus fulvestrant treatment in patients with HR+/HER2- advanced BC.

Posted by on Sep 18, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of palbociclib (Ibrance) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding palbociclib to fulvestrant was safe and significantly improved the overall survival over the...

Read More

Comparing the effectiveness of epirubicin and cyclophosphamide plus taxanes versus carboplatin plus taxanes in early-stage triple‑negative breast cancer.

Comparing the effectiveness of epirubicin and cyclophosphamide plus taxanes versus carboplatin plus taxanes in early-stage triple‑negative breast cancer.

Posted by on Dec 5, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of epirubicin (Ellence) and cyclophosphamide (Cytoxan) plus paclitaxel (Taxol)/docetaxel (Taxotere) (taxanes) (ECT) versus carboplatin (Paraplatin) plus taxanes (TP) regimens in patients with early-stage triple-negative breast cancer (TNBC). The data showed that both treatment regimens showed...

Read More

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Posted by on Jul 24, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated if there were any clinical indicators to identify which patients with advanced melanoma would benefit from immune checkpoint blocker (ICB) therapy. The data showed that blood LDH levels, the extent of disease, number of white blood cells, and immune-related side effects were all associated with better...

Read More

Could patient-reported outcomes predict survival benefits in patients with advanced breast cancer treated with abemaciclib?

Could patient-reported outcomes predict survival benefits in patients with advanced breast cancer treated with abemaciclib?

Posted by on Jun 13, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the association between patient-reported outcomes (PROs) and survival outcomes in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC) treated with abemaciclib (Verzenio). The data showed that the PROs could be a predictor of survival benefits in these patients. Some...

Read More

Adding everolimus to letrozole in premenopausal patients with hormone-positive advanced breast cancer

Adding everolimus to letrozole in premenopausal patients with hormone-positive advanced breast cancer

Posted by on Jun 6, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the effects and outcomes of adding everolimus (EVE; Afinitor) plus letrozole (LET; Femara) to hormonal therapy for the treatment of premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (BC). The data showed that the combination of EVE+LET improved survival...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Breast cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including breast cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Comparing the effectiveness of different chemotherapy regimens after surgery in early stage breast cancer

Comparing the effectiveness of different chemotherapy regimens after surgery in early stage breast cancer

Posted by on Apr 21, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of current chemotherapy regimens for treatment in patients with early-stage breast cancer (BC). The data showed that the current treatment regimens have similar effectiveness. Some background BC is classified into different subtypes depending on the presence or...

Read More

Can abemaciclib plus hormonal therapy be considered a safe and effective treatment in older patients with advanced breast cancer?

Can abemaciclib plus hormonal therapy be considered a safe and effective treatment in older patients with advanced breast cancer?

Posted by on Apr 3, 2021 in Breast cancer | 0 comments

In a nutshell This article looked at the safety and effectiveness of abemaciclib (Verzenios) plus hormonal therapy (HT) in older patients with hormone receptor-positive (HR+)/HER-2 negative (HER2-) advanced breast cancer (BC). The authors concluded that abemaciclib + HT was effective across all age groups and while higher rates of side effects...

Read More

Is heart monitoring needed in patients with HER2-positive metastatic breast cancer using trastuzumab?

Is heart monitoring needed in patients with HER2-positive metastatic breast cancer using trastuzumab?

Posted by on Feb 20, 2021 in Breast cancer | 0 comments

In a nutshell This article looked at the occurrence of heart-related side effects in patients with HER2-positive metastatic breast cancer (mBC) receiving trastuzumab (Herceptin). The authors found that non-smoking patients with a good heart function before receiving treatment have a low risk of heart toxicity (HT) after 4 years...

Read More

Pembrolizumab plus chemotherapy can delay progression of advanced triple negative breast cancer

Pembrolizumab plus chemotherapy can delay progression of advanced triple negative breast cancer

Posted by on Dec 31, 2020 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of pembrolizumab (Keytruda) plus chemotherapy in patients with inoperable or metastatic triple-negative breast cancer. The data showed that the combination is effective in improving progression-free survival in these patients. Some background Triple-negative breast cancer (TNBC)...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2025 Medivizor